Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration.
Context. - Time to development of acquired immunodeficiency syndrome (AIDS) and time to death have been extended with the increased use of combination therapy and protease inhibitors.
Cohort studies following up persons with human immunodeficiency virus (HIV) infection in periods characterized by different therapies offer the opportunity to estimate therapy effectiveness at the population level.
- To assess the effectiveness of self-reported, long-term potent antiretroviral therapy in a cohort of 536 men whose duration of HIV infection was known (seroconverters).
- Cohort study.
The cohort was compared for time to development of AIDS and time to death in 1984 to 1990,1990 to 1993,1993 to July 1995, and July 1995 to July 1997 when the major treatments were no therapy, monotherapy, combined therapy, and potent antiretroviral therapy, respectively.
Survival analysis methods with time zero set as the date of seroconversion and incorporating staggered entries into each period were used.
Mean CD4 cell change, stratified by infection duration, was determined for each period using a random effects model.
- The Multicenter AIDS Cohort Study (MACS) in 4 urban areas (Baltimore, Md ; Chicago, III ; Los Angeles, Calif ; and Pittsburgh, Pa).
- A total of 5622 men who were 18 years or older were enrolled into MACS.
Of the 5622, there were 2191 HIV-positive individuals at enrollment. (...)
Mots-clés Pascal : SIDA, Virose, Infection, Virus immunodéficience humaine, Lentivirus, Retroviridae, Virus, Etude cohorte, Antiviral, Chimiothérapie, Efficacité traitement, Long terme, Sérologie, Homme, Mortalité, Immunopathologie, Immunodéficit, Immunomodulateur, Antirétroviral, Séroconversion
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Human immunodeficiency virus, Lentivirus, Retroviridae, Virus, Cohort study, Antiviral, Chemotherapy, Treatment efficiency, Long term, Serology, Human, Mortality, Immunopathology, Immune deficiency, Immunomodulator
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0526619
Code Inist : 002B05C02D. Création : 23/03/1999.